Compare Davita Inc (DVA) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares Silver Trust — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while iShares Silver Trust trades at $54.88 (market cap $29.02B). The key difference: iShares Silver Trust is far larger — about 2.6× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and iShares Silver Trust for 89 Days on average.
| DVA | SLV | |
|---|---|---|
Market Cap | $11.29B | $29.02B |
Volume | 582,204 | 16,510,334 |
Sector | Health | — |
52-Week High | $240.96 | $105.57 |
52-Week Low | $103.87 | $42.40 |
Typical Hold Time | 114 Days | 89 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
SLV trades at $54.78, up 1.78% today, but faces a bearish technical outlook with 18 sell signals versus 4 buy signals. The company reported $2.17M net income for 2024 despite zero revenue, with total assets surging to $13.41B from $10M in 2023. Recent news highlights silver's volatility amid Fed policy uncertainty and rising Treasury yields.
Outlook remains cautious given technical weakness and macroeconomic pressures on precious metals. The asset growth without corresponding revenue generation raises fundamental concerns, while institutional sentiment appears mixed amid silver's recent price decline of nearly 50% from recent highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
